2026-06-14T03:38:23Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/147722024-11-29T14:46:43Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597
Repisalud
author
Blasco, María Teresa
author
Navas, Carolina
author
Martín-Serrano, Guillermo
author
Martín-Díaz, Laura
author
Li, Jing
author
Morales-Cacho, Lucia
author
Esteban-Burgos, Laura
author
Perales-Patón, Javier
author
Bousquet-Mur, Emilie
author
Castellano, Eva
author
Jacob, Harrys K C
author
Cabras, Lavinia
author
Sainz, Bruno
author
Dusetti, Nelson
author
Iovanna, Juan
author
Sánchez-Bueno, Francisco
author
Hidalgo, Manuel
author
Khiabanian, Hossein
author
Rabadán, Raul
author
Graña Castro, Osvaldo
author
Lechuga C, Lechuga CG
author
Djurec M, Djurec M
author
Musteanu, Mónica
author
Drosten, Matthias
author
Ortega Jimenez, Sagrario
author
Mulero, Francisca
author
Guerra, Carmen
author
Barbacid, Mariano
author
Al-Shahrour, Fatima
funder
Unión Europea. Comisión Europea. European Research Council (ERC)
funder
Unión Europea. Comisión Europea
funder
Asociación Española Contra el Cáncer
funder
Ligue Nationale Contre le Cancer (Francia)
funder
United States Department of Health and Human Services
funder
Deutsche Forschungsgemeinschaft (Alemania)
funder
Ministerio de Ciencia e Innovación (España)
funder
Fundación La Caixa
funder
Ministerio de Economía, Industria y Competitividad (España)
funder
Fundación AXA
2022-07-27T10:56:57Z
2022-07-27T10:56:57Z
2019-04-15
Cancer Cell . 2019;35(4):573-587.e6.
10.1016/j.ccell.2019.03.002
1878-3686
Cancer cell
30975481
http://hdl.handle.net/20.500.12105/14772
Five-year survival for pancreatic ductal adenocarcinoma (PDAC) patients remains below 7% due to the lack of effective treatments. Here, we report that combined ablation of EGFR and c-RAF expression results in complete regression of a significant percentage of PDAC tumors driven by Kras/Trp53 mutations in genetically engineered mice. Moreover, systemic elimination of these targets induces toxicities that are well tolerated. Response to this targeted therapy correlates with transcriptional profiles that resemble those observed in human PDACs. Finally, inhibition of EGFR and c-RAF expression effectively blocked tumor progression in nine independent patient-derived xenografts carrying KRAS and TP53 mutations. These results open the door to the development of targeted therapies for PDAC patients.
eng
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.
journal article
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
URL
https://repisalud.isciii.es/bitstreams/372edd27-5313-44fa-a10a-31778344e9eb/download
File
MD5
8181a0f6b1f0944211a4c90569649fc8
8292699
application/pdf
completeregressionofadvancedpancreatic_2019.pdf
URL
https://repisalud.isciii.es/bitstreams/8e546a11-5719-47af-9ae2-792abc346ade/download
File
MD5
575599eca531f98d35c4e1ccc4ffea68
28105404
application/pdf
1-s2.0-S1535610819301114-mmc1.pdf
URL
https://repisalud.isciii.es/bitstreams/fdcf3b3d-b3ef-4d15-a406-dab71962a7c9/download
File
MD5
504edd88c357ce5775a0d1ac3d89c9a4
1320620
application/vnd.openxmlformats-officedocument.spreadsheetml.sheet
Copia de 1-s2.0-S1535610819301114-mmc2.xlsx
URL
https://repisalud.isciii.es/bitstreams/687f5a1f-22ed-4a33-ac52-281302607dda/download
File
MD5
c972d4adff95b0eba321706c91ea537a
83497
text/plain
completeregressionofadvancedpancreatic_2019.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/cb0cad35-8f26-4cbc-a7a1-538b9647ff09/download
File
MD5
a6d33f0da531a9b92f4bb28ab5464378
7311
text/plain
1-s2.0-S1535610819301114-mmc1.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/48bb6169-353c-4234-9dc5-28385b7a260d/download
File
MD5
32d1febc2cec661a8c5d712c23a11991
100000
text/plain
Copia de 1-s2.0-S1535610819301114-mmc2.xlsx.txt